Skip to main content
. Author manuscript; available in PMC: 2024 Jul 11.
Published in final edited form as: Adv Funct Mater. 2023 Apr 14;33(28):2300218. doi: 10.1002/adfm.202300218

Figure 2. TBI-ABN contains a calpain FRET substrate peptide that can be quantified via fluorescence and ELISA.

Figure 2.

a. Schematic of TBI-ABN, which releases a cleaved peptide (c-Peptide) biomarker after cleavage of the peptide substrate by calpain-1. b. In vitro cleavage kinetics of free peptide (left) and peptide and VT750 conjugated to PEG to form TBI-ABN (right), incubated with human calpain-1 (n = 3 technical replicates, mean ± SD). c. Michaelis-Menten curves derived from the maximal velocities of cleavage (n = 3 technical replicates, mean ± SD). d. Dynamic range of free peptide and TBI-ABN on a sandwich ELISA, with α-FAM as the capture antibody and streptavidin-HRP as the detection molecule. (n = 3 technical replicates, mean ± SD, dashed line denotes the limit of detection (LOD)).